Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis.

Rovina RuslamiFajri GafarVycke YunivitaIda ParwatiAhmad R GaniemRob E AarnoutseBob WilffertJan-Willem C AlffenaarHeda M Nataprawira

Published in: Archives of disease in childhood (2021)

Higher rifampicin doses are strongly warranted in treatment of children and adolescents with TBM. The association between higher plasma concentrations of isoniazid, rifampicin and pyrazinamide and the development of DILI needs confirmatory studies.

Keyphrases

mycobacterium tuberculosis
pulmonary tuberculosis
clinical trial
combination therapy
case control
double blind
study protocol